B. Riley Analysts Decrease Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at B. Riley cut their Q2 2025 EPS estimates for shares of Harrow in a research note issued to investors on Monday, March 31st. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.17 per share for the quarter, down from their prior estimate of $0.25. B. Riley currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s Q3 2025 earnings at $0.21 EPS and Q4 2025 earnings at $0.38 EPS.

Harrow (NASDAQ:HROW) last released its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The company had revenue of $66.83 million for the quarter, compared to the consensus estimate of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%.

Separately, HC Wainwright reiterated a “buy” rating and issued a $57.00 target price on shares of Harrow in a report on Monday.

Harrow Stock Up 4.3 %

HROW stock opened at $26.05 on Wednesday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock’s 50 day simple moving average is $28.36 and its 200 day simple moving average is $37.63. Harrow has a fifty-two week low of $9.86 and a fifty-two week high of $59.23. The company has a market cap of $927.77 million, a P/E ratio of -27.71 and a beta of 0.69.

Institutional Investors Weigh In On Harrow

A number of hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in Harrow during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC increased its stake in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Harrow in the fourth quarter valued at approximately $78,000. AlphaQuest LLC grew its holdings in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock valued at $118,000 after purchasing an additional 2,889 shares during the period. Finally, Federated Hermes Inc. purchased a new stake in Harrow in the fourth quarter worth $214,000. 72.76% of the stock is currently owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.